Sept 21 (Reuters) – ADARx Pharmaceuticals is targeting a valuation of up to $1.74 billion in its US initial public offering, the company developing RNA drugs said on Monday. The company is aiming to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
* Russia doubled diesel exports to Central Asia to 370,000 tons * Mongolia remains the…
Sept 21 (Reuters) - Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered…
FRANKFURT, Sept 21 (Reuters) - The European Central Bank launched a new service on Monday…
NOVO NORDISK US HEAD: 50% OF ENTIRE WEGOVY FRANCHISE AND 90% OF WEGOVY PILL US…
VIDEO SHOWS: FILE FOOTAGE OF SWITZERLAND MIDFIELDER GRANIT XHAKA SHOWS: VANCOUVER, CANADA (JULY 5, 2026)…
NOVO NORDISK US HEAD: NOVO HAS GAINED ROUGHLY 8 SHARE POINTS IN OBESITY SINCE JANUARY…